1,2,3‐Triazole hybrids as anticancer agents: A review

Abstract

Despite the advancements in the development of anticancer agents, more effective and safer anticancer drugs still need to be developed as the current agents cause unwanted side effects and many patients have become drug resistant. 1,2,3-Triazoles, due to their remarkable biological potential, have received considerable attention in drug discovery for the development of anticancer agents. The present review article presents an overview of the recent advances in 1,2,3-triazole hybrids with anticancer potential over the last 2 years, their chemical structures, structure-activity relationships, and mechanisms of action, as well as insights into the docking studies.

Design, synthesis, anticancer activity and molecular docking studies of new benzimidazole derivatives bearing 1,3,4-oxadiazole moieties as potential thymidylate synthase inhibitors

“…29 Du et al and others have reported 1,3,4-oxadiazole derivatives as potent TS inhibitors. 30,31 Besides this, 1,2,3-triazole derivatives have exerted an anticancer effect by inhibition of the thymidylate synthase enzyme 32,33 (Fig. 1).…”

Cyanoacetohydrazide linked to 1,2,3-triazole derivatives: a new class of α-glucosidase inhibitors

“…The “click” in click chemistry refers to the rapid and selective reactions of small molecules leading to the formation of a wide range of products 25 . Among many click reactions described to date, copper (I)-catalyzed alkyne-azide cycloaddition introduced by Sharpless et al 26 has attracted much attention due to the potency of production of a library of bioactive 1,2,3-triazole derivatives through heteroatom links 27 – 32 . The α-glucosidase inhibitory activity of 1,2,3-triazoles have also been fully investigated in the literature 33 as a prime choice for medicinal researchers to develop new anti-DM molecules.…”

Design and synthesis of new bis(1,2,4-triazolo[3,4-b][1,3,4]thiadiazines) and bis((quinoxalin-2-yl)phenoxy)alkanes as anti-breast cancer agents through dual PARP-1 and EGFR targets inhibition

“…Anticancer effects have been documented for 1,2,4-triazoles, 34 quinoxalines, 35 and 1,2,4-triazolo[3,4- b ]thiadiazines, 27,28 that all work in various ways. They work by inhibiting the enzymes including PARP-1 and EGFR, which are involved in cancer progression.…”